Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > As predicted. shorting away

<< Previous

Bullboard Posts

Next >>

Post by canadafanon May 15, 2024 1:47pm

188 Views

Post# 36041585

As predicted. shorting away

As predicted, the shorters are trying real hard.
The S.P. is down, becuase it is being shorted and/or the ATM.
Todays news is nothing short of exceptional.
Which the exact words "acclerated approval " is not used. The definiation of the trial, which will be enrolled ASSAP ( read the N.R..dont take my word), will be designed to utilize exiting & previous tratment resutls. Meaning the whole trial will be smaller,quicker and if sucsessful will yeild quick approval to use. AKA license enabling trial.
Read the N.R. Dont take my word & certialnly not the team of on-going brainless bashiing.

<< Previous

Bullboard Posts

Next >>

Three mispriced stocks exposed to major market tailwinds